# Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer

> **NCT05507593** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 18 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **BIOLOGICAL:** DLL3-CAR-NK cells

## Key facts

- **NCT ID:** NCT05507593
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507593, "Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05507593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*